New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
08:10 EDTLJPCLa Jolla Pharmaceutical, GW University enter into agreement related to LJPC-501
La Jolla Pharmaceutical announced that it has signed an option agreement with the George Washington University that will add proprietary technology to the company’s LJPC-501 program. The option agreement with GW adds potential proprietary protection to La Jolla’s pipeline, which includes treatments for chronic kidney disease, hepatorenal syndrome, chronic iron overload, and rare diseases.
News For LJPC From The Last 14 Days
Check below for free stories on LJPC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 15, 2014
09:21 EDTLJPCOn The Fly: Pre-market Movers
Subscribe for More Information
08:01 EDTLJPCLa Jolla Pharma announces pre-clinical data for LJPC-1010 in NASH
Subscribe for More Information
July 11, 2014
11:39 EDTLJPCLa Jolla price target raised to $45 from $34 at Wedbush
Subscribe for More Information
July 9, 2014
15:35 EDTLJPCLa Jolla price target raised to $38 on '501 potential in CRH at Noble Financial
05:34 EDTLJPCLa Jolla to host investor conference call
Subscribe for More Information
July 8, 2014
16:03 EDTLJPCLa Jolla plans initiation of Phase 3 registration program for LJPC-501 for CRH
La Jolla Pharmaceutical announced that the company plans to begin a phase 3 registration program for LJPC-501 for the treatment of catecholamine-resistant hypotension, a new indication. Initiation of this registration program is the result of a recent meeting between the company and the FDA at which agreement was reached that blood pressure is an appropriate primary endpoint for approval. Due to the estimated size of the patient population in the United States for this indication, the company has filed for Orphan Drug status for angiotensin II.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use